Skip to main content
DVAX
NASDAQ Life Sciences

Dynavax Board Unanimously Recommends Sanofi's $15.50/Share All-Cash Tender Offer for Acquisition

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
10
Price
$15.38
Mkt Cap
$1.81B
52W Low
$9.2
52W High
$15.49
Market data snapshot near publication time

Summary

Sanofi is acquiring Dynavax Technologies Corporation for $15.50 per share in an all-cash tender offer, a transaction unanimously recommended by Dynavax's Board of Directors.


Key Events

  • Acquisition Agreement

    Sanofi, through its subsidiary Samba Merger Sub, Inc., is acquiring Dynavax Technologies Corporation for $15.50 per share in an all-cash tender offer.

  • Board Recommendation

    Dynavax's Board of Directors unanimously recommends that shareholders tender their shares, citing the offer as advisable and in the best interest of the company and its stockholders.

  • Significant Premium

    The $15.50 per share offer price represents a premium of approximately 39% to Dynavax's closing price on December 23, 2025, and 46% to the 90-day volume-weighted average price. The offer price is also near the stock's 52-week high of $15.49.

  • Certainty of Value

    The all-cash consideration provides immediate and certain value to shareholders, mitigating risks associated with Dynavax's standalone strategy and pipeline development.


Analysis

The SC 14D9 filing confirms that Dynavax Technologies Corporation's Board of Directors unanimously recommends shareholders accept Sanofi's all-cash tender offer of $15.50 per share. This acquisition provides immediate and certain value to Dynavax shareholders, representing a substantial premium of approximately 39% to the stock's closing price on December 23, 2025, and 46% to the 90-day volume-weighted average price. The board's decision follows an extensive evaluation of strategic alternatives and negotiations, concluding that Sanofi's offer represents the best available option for maximizing shareholder value. The all-cash nature and the structure as a tender offer followed by a short-form merger indicate a high likelihood of timely consummation, offering a clear exit for investors near the stock's 52-week high.

At the time of this filing, DVAX was trading at $15.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.20 to $15.49. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DVAX - Latest Insights

DVAX
Feb 10, 2026, 9:10 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $15.49
Real-time Price: $15.49 info
Change: $0 (0%) info
Market Cap: $1.82B info
DVAX
Feb 10, 2026, 6:36 AM EST
Filing Type: SC 14D9/A
Importance Score:
9
Price at Filing: $15.49
Real-time Price: $15.49 info
Change: $0 (0%) info
Market Cap: $1.82B info
DVAX
Jan 30, 2026, 8:05 AM EST
Filing Type: SC 14D9/A
Importance Score:
7
Price at Filing: $15.48
Real-time Price: $15.49 info
Change: +$0.0101 (+0.07%) info
Market Cap: $1.82B info
DVAX
Jan 28, 2026, 6:50 AM EST
Filing Type: SC 14D9/A
Importance Score:
8
Price at Filing: $15.48
Real-time Price: $15.49 info
Change: +$0.0101 (+0.07%) info
Market Cap: $1.82B info
DVAX
Jan 12, 2026, 7:32 AM EST
Filing Type: SC 14D9
Importance Score:
10
Price at Filing: $15.38
Real-time Price: $15.49 info
Change: +$0.1101 (+0.72%) info
Market Cap: $1.82B info